查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1918193

辅助生殖技术市场－2026-2031年预测

Assisted Reproductive Technology Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 143 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

辅助生殖技术（ART）市场预计将从 2025 年的 335.39 亿美元成长到 2031 年的 472.49 亿美元，复合年增长率为 5.88%。

辅助生殖技术（ART）市场涵盖了治疗不孕症的先进且快速发展的生殖技术领域，包括体外操作卵子、精子和胚胎的技术。该市场的特点是投入巨大，既有情感因素，也有经济因素，其驱动力源于患者的迫切需求以及旨在提高成功率和扩大服务覆盖范围的持续科学进步。

核心临床操作流程与治疗范围

辅助生殖技术（ART）是指透过手术采集卵子，在实验室中与精子结合，然后将形成的胚胎植入子宫或冷冻保存。体外受精（IVF）是辅助生殖技术的基础和最广泛应用的技术。辅助生殖技术市场不仅限于IVF，还包括卵胞浆内单一精子注射（ICSI）、胚胎胚胎着床前遗传学检测（PGT）、卵子/精子/胚胎冷冻保存以及第三方辅助生殖（卵子/精子捐赠和代孕）等相关技术。这套全面的服务涵盖了多种不孕症病因，从输卵管因素和男性不孕症到不明原因不孕症以及与老龄化相关的卵子品质下降。

主要市场成长要素

成长要素是全球不孕症盛行率的不断上升，而这又是由生活方式和医疗因素的复杂交互作用所造成的。这些因素包括初次生育年龄的增长、卵巢症候群（PCOS）和子宫内膜异位症等疾病发生率的上升、肥胖率的上升以及环境因素。不断扩大的患者群体对有效的不孕症治疗产生了持续的需求。

同时，重要的社会人口结构变化正在重塑患者群体。尤其是在已开发国家，生育年龄延迟的趋势导致自然生育率下降，增加了对辅助生殖技术（ART）的依赖。此外，社会对其他家庭形式的接受度不断提高，法律也逐渐认可了包括单亲家庭和同性伴侣在内的各种家庭形式，这催生了大规模需要辅助生殖技术服务（通常涉及捐精和代孕）来组建家庭的新患者群体，从而扩大了潜在的市场目标群体。

技术和流程创新是市场成长和差异化的关键催化剂。持续改善旨在提高成功率、减轻治疗负担并提升安全性。重点研发领域包括：改进培养基和延时胚胎观察技术以更好地筛选胚胎；进行全面的基因筛检以识别卵母细胞和胚胎（PGT-A）；改进玻璃化冷冻技术以提高卵子细胞和胚胎冷冻保存的效率；以及开发更温和的促排卵通讯协定。诸如体内培养系统（如阴道内培养）等创新技术，体现了使治疗更便捷、创伤更小的努力。

社会对不孕症认知的提升以及相关污名的消除，是推动市场扩张的强大动力。专业协会、病患支持团体和生育诊所积极进行的教育活动，使不孕症治疗成为人们普遍关注的议题，鼓励更多个人和夫妻儘早寻求评估和治疗。这种认知的提升，加上媒体报告的增加，正在推动患者数量和服务需求的成长。

支持性且多元化的监管环境和报销体係也会影响市场动态。在保险覆盖范围广、公共资金支持体外受精（ART）週期的地区，ART的普及率和使用率显着更高。不断演变的第三方辅助生殖和胚胎研究相关法律制度也在影响不同地区市场的服务可近性和商业策略。

区域情势和趋势

欧洲是一个成熟且重要的市场，其特点是手术量大、法规结构完善，许多国家都有强大的公共资金和保险覆盖，这促进了高利用率和竞争格局。

北美凭藉其强大的私人保险市场、较高的自付费用能力以及众多大型研究和商业实验室，在技术应用和高价值治疗週期方面处于主导。它是PGT（胚胎着床前遗传学检测）和卵子冷冻保存等先进技术大规模应用和商业化的先驱地区。

亚太地区因其庞大的人口基数、不断增长的可支配收入、不孕不育治疗医疗旅游的蓬勃发展以及对不孕不育和辅助生殖技术（ART）的文化偏见逐渐减少，而被公认为高增长市场。医疗基础设施的改善和大型连锁不孕症诊所的兴起正在加速该地区的市场发展。

竞争格局与策略重点

竞争环境是多方面的，包括大型上市的生育诊所连锁机构、独立且成功率高的诊所、专门从事生育治疗药物的製药公司以及专业实验室设备和耗材的製造商。

策略竞争的重点在于提供卓越的临床结果（活产率）、优质的病患体验和全面的服务。领先的诊所大力投资先进的实验室技术，聘请知名的胚胎学家，并提供包括遗传学、捐卵计画和代孕协调在内的综合服务。此外，透过收购和建构整合网路来拓展地域范围，也是提升市场占有率的策略重点。

未来市场趋势

辅助生殖技术（ART）市场的未来发展方向是更个人化、更深入的遗传学知识和更高的效率。将人工智慧（AI）和机器学习应用于胚胎选择和週期预测是一项重要的前沿技术。透过粒线体替代疗法和体外精子发生等技术来缓解老龄化相关性不孕症的研究，则指向一个更长远的未来。

市场成长也将受到提高可负担性和可及性的努力的推动，这些努力包括透过成本控制治疗模式、扩大保险覆盖范围和简化技术，然而，围绕基因选择、胚胎处置和第三方辅助生殖的复杂伦理、法律和社会问题仍需继续解决。

行业相关人员的成功取决于保持技术领先地位、提供富有同情心且有效的患者照护，以及应对日益激烈的全球竞争和监管环境。随着社会趋势持续向高龄生产和家庭结构多样化发展，在人类持久的愿望和生殖医学科学技术的不断进步的推动下，辅助生殖技术（ART）市场预计将继续扩张。

本报告的主要优势：

  • 深入分析：获得主要和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、行业垂直领域和其他细分市场。
  • 竞争格局：了解全球主要参与者的策略倡议，并了解透过正确的策略进入市场的机会。
  • 市场驱动因素与未来趋势：探讨影响市场的动态因素和关键趋势及其对未来市场发展的影响。
  • 可操作的建议：利用这些见解，在动态环境中做出策略决策，并开拓新的商机和收入来源。
  • 受众广泛：适用于Start-Ups、研究机构、顾问公司、中小企业和大型企业，且经济实惠。

它是用来做什么的？

产业与市场分析、机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法规结构及影响、新产品开发、竞争情报

报告范围：

  • 2022年至2024年的历史数据和2025年至2031年的预测数据
  • 成长机会、挑战、供应链前景、法规结构与趋势分析
  • 竞争定位、策略和市场占有率分析
  • 按业务板块和地区（包括国家）分類的收入和预测评估
  • 公司概况（策略、产品、财务资讯、关键发展等）

目录

第一章执行摘要

第二章 市场概览

  • 市场概览
  • 市场定义
  • 调查范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策与法规
  • 策略建议

第四章 技术展望

第五章 按技术分類的辅助生殖技术市场

  • 介绍
  • 体外受精（IVF）
  • 人工授精（AI）
  • 冷冻胚胎移植（FET）
  • 代孕
  • 其他的

6. 辅助生殖技术市场（依手术类型划分）

  • 介绍
  • 新捐赠者
  • 新鲜非捐赠者
  • 冷冻捐赠者
  • 冷冻非捐赠者

7. 依最终用户分類的辅助生殖技术市场

  • 介绍
  • 医院
  • 不孕不育诊所
  • 冷冻库
  • 研究所

8. 各地区辅助生殖技术市场

  • 介绍
  • 北美洲
    • 透过技术
    • 透过治疗
    • 最终用户
    • 按国家/地区
      • 我们
      • 加拿大
      • 墨西哥
  • 南美洲
    • 透过技术
    • 透过治疗
    • 最终用户
    • 按国家/地区
      • 巴西
      • 阿根廷
      • 其他的
  • 欧洲
    • 透过技术
    • 透过治疗
    • 最终用户
    • 按国家/地区
      • 英国
      • 德国
      • 法国
      • 西班牙
      • 其他的
  • 中东和非洲
    • 透过技术
    • 透过治疗
    • 最终用户
    • 按国家/地区
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 其他的
  • 亚太地区
    • 透过技术
    • 透过治疗
    • 最终用户
    • 按国家/地区
      • 中国
      • 日本
      • 印度
      • 韩国
      • 台湾
      • 其他的

第九章 竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 合併、收购、协议和合作
  • 竞争对手仪錶板

第十章：公司简介

  • FUJIFILM Irvine Scientific
  • Merck KGaA
  • Vitrolife AB
  • CooperSurgical, Inc.
  • Thermo Fisher Scientific Inc.
  • Cook Medical
  • Genea Biomedx
  • IMV Technologies
  • Ferring Pharmaceuticals
  • IVFtech ApS

第十一章附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要收益
  • 调查方法
  • 简称
简介目录
Product Code: KSI061616022

Assisted Reproductive Technology Market, with a 5.88% CAGR, is forecasted to expand from USD 33.539 billion in 2025 to USD 47.249 billion in 2031.

The assisted reproductive technology (ART) market encompasses a sophisticated and rapidly evolving segment of reproductive medicine dedicated to treating infertility through laboratory-based manipulation of eggs, sperm, and embryos. This market is characterized by high emotional and financial investment, driven by profound patient need and continuous scientific advancement aimed at improving success rates and expanding access.

Core Clinical Procedures and Treatment Spectrum

ART refers to procedures where eggs are surgically retrieved, combined with sperm in a laboratory setting, and the resulting embryo(s) are transferred to the uterus or cryopreserved. In-vitro fertilization (IVF) is the cornerstone and most prevalent ART procedure. The market extends beyond IVF to include associated technologies such as intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), egg/sperm/embryo cryopreservation, and third-party reproduction (donor eggs/sperm, gestational surrogacy). This comprehensive suite of services addresses a wide range of infertility etiologies, from tubal factors and male factor infertility to unexplained infertility and age-related decline in oocyte quality.

Primary Market Growth Drivers

A fundamental and persistent driver is the rising global prevalence of infertility, attributed to a complex interplay of lifestyle and medical factors. These include increasing maternal age at first conception, higher rates of conditions like polycystic ovary syndrome (PCOS) and endometriosis, rising obesity levels, and environmental factors. This expanding patient base creates sustained demand for effective fertility treatments.

Concurrent with this, significant sociodemographic shifts are reshaping the patient population. The trend toward delayed childbearing, particularly in developed economies, increases reliance on ART as natural fertility declines. Furthermore, growing social acceptance and legal recognition of alternative family structures-including single parents by choice and same-sex couples-are creating new and substantial patient cohorts who require ART services (often with donor gametes or surrogacy) to build families, thereby broadening the market's addressable base.

Technological and procedural innovation is a critical catalyst for market growth and differentiation. Continuous improvements aim to enhance success rates, reduce treatment burden, and improve safety. Key areas of advancement include: refined culture media and time-lapse embryo imaging for better embryo selection; comprehensive genetic screening (PGT-A) to identify euploid embryos; vitrification techniques for highly effective egg and embryo freezing; and the development of milder stimulation protocols. Innovations like in-vivo culture systems (e.g., intravaginal culture) represent efforts to make treatment more accessible and less invasive.

Increased public awareness and destigmatization of infertility are powerful market enablers. Proactive educational efforts by professional societies, patient advocacy groups, and fertility clinics have normalized discussions around fertility treatment, encouraging more individuals and couples to seek evaluation and care earlier. This increased awareness, coupled with growing media coverage, drives patient volumes and demand for services.

Supportive, though varied, regulatory and reimbursement landscapes also influence market dynamics. In regions with favorable insurance mandates or public funding for ART cycles, access and utilization are significantly higher. Evolving legal frameworks governing third-party reproduction and embryo research also shape service availability and commercial strategies across different geographic markets.

Geographic Landscape and Regional Dynamics

Europe represents a mature and significant market, characterized by high procedure volumes, well-established regulatory frameworks, and often substantial public funding or insurance coverage in many countries. This support fosters high utilization rates and a competitive clinic landscape.

North America is a leader in technological adoption and high-value treatment cycles, driven by a robust private-payer market, significant out-of-pocket spending capacity, and a concentration of leading research institutions and commercial laboratories. The region is often the first to adopt and commercialize advanced techniques like PGT and egg freezing on a large scale.

The Asia-Pacific region is identified as a high-growth market, fueled by large populations, rising disposable incomes, increasing medical tourism for fertility services, and gradually decreasing cultural stigma surrounding infertility and ART. Improving healthcare infrastructure and the emergence of large, chain-owned fertility clinics are accelerating market development in this region.

Competitive Landscape and Strategic Focus

The competitive environment is multifaceted, including large publicly-traded fertility clinic chains, independent high-success-rate clinics, pharmaceutical companies specializing in fertility drugs, and manufacturers of specialized laboratory equipment and consumables.

Strategic competition centers on demonstrating superior clinical outcomes (live birth rates), patient experience, and service range. Leading clinics invest heavily in advanced laboratory technologies, recruit renowned embryologists, and offer comprehensive services including genetics, donor programs, and surrogacy coordination. There is also a strategic focus on geographic expansion through acquisition and the development of integrated networks to capture market share.

Future Market Trajectory

The future trajectory of the ART market is oriented toward greater personalization, genetic insight, and efficiency. The integration of artificial intelligence and machine learning for embryo selection and cycle prediction is a major frontier. Research into mitigating age-related infertility, through techniques like mitochondrial replacement or in-vitro gametogenesis, represents a longer-term horizon.

Market growth will also be influenced by efforts to improve affordability and access through cost-contained treatment models, insurance expansion, and technological simplification. However, the market will continue to navigate complex ethical, legal, and social considerations surrounding genetic selection, embryo disposition, and third-party reproduction.

Success for industry participants will depend on maintaining technological leadership, delivering compassionate and effective patient care, and navigating an increasingly competitive and regulated global landscape. As societal trends toward later parenthood and diverse family formation continue, the ART market is poised for sustained expansion, driven by deep-seated human aspirations and the relentless pursuit of scientific progress in reproductive medicine.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2022 to 2024 & forecast data from 2025 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Assisted Reproductive Technology Market Segmentation

  • By Technique
  • In Vitro Fertilization (IVF)
  • Artificial Insemination (AI)
  • Frozen Embryo Transfer (FET)
  • Surrogacy
  • Others
  • By Procedure
  • Fresh Donor
  • Fresh Non-Donor
  • Frozen Donor
  • Frozen Non-Donor
  • By End-User
  • Hospitals
  • Fertility Clinics
  • Cryobanks
  • Research Institutes
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Taiwan
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. ASSISTED REPRODUCTIVE TECHNOLOGY MARKET BY TECHNIQUE

  • 5.1. Introduction
  • 5.2. In Vitro Fertilization (IVF)
  • 5.3. Artificial Insemination (AI)
  • 5.4. Frozen Embryo Transfer (FET)
  • 5.5. Surrogacy
  • 5.6. Others

6. ASSISTED REPRODUCTIVE TECHNOLOGY MARKET BY PROCEDURE

  • 6.1. Introduction
  • 6.2. Fresh Donor
  • 6.3. Fresh Non-Donor
  • 6.4. Frozen Donor
  • 6.5. Frozen Non-Donor

7. ASSISTED REPRODUCTIVE TECHNOLOGY MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Fertility Clinics
  • 7.4. Cryobanks
  • 7.5. Research Institutes

8. ASSISTED REPRODUCTIVE TECHNOLOGY MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Technique
    • 8.2.2. By Procedure
    • 8.2.3. By End-User
    • 8.2.4. By Country
      • 8.2.4.1. USA
      • 8.2.4.2. Canada
      • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Technique
    • 8.3.2. By Procedure
    • 8.3.3. By End-User
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
      • 8.3.4.2. Argentina
      • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Technique
    • 8.4.2. By Procedure
    • 8.4.3. By End-User
    • 8.4.4. By Country
      • 8.4.4.1. United Kingdom
      • 8.4.4.2. Germany
      • 8.4.4.3. France
      • 8.4.4.4. Spain
      • 8.4.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Technique
    • 8.5.2. By Procedure
    • 8.5.3. By End-User
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
      • 8.5.4.2. UAE
      • 8.5.4.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Technique
    • 8.6.2. By Procedure
    • 8.6.3. By End-User
    • 8.6.4. By Country
      • 8.6.4.1. China
      • 8.6.4.2. Japan
      • 8.6.4.3. India
      • 8.6.4.4. South Korea
      • 8.6.4.5. Taiwan
      • 8.6.4.6. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. FUJIFILM Irvine Scientific
  • 10.2. Merck KGaA
  • 10.3. Vitrolife AB
  • 10.4. CooperSurgical, Inc.
  • 10.5. Thermo Fisher Scientific Inc.
  • 10.6. Cook Medical
  • 10.7. Genea Biomedx
  • 10.8. IMV Technologies
  • 10.9. Ferring Pharmaceuticals
  • 10.10. IVFtech ApS

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key Benefits for the Stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations